In recent trading session, Johnson & Johnson (NYSE:JNJ) saw 1.88 million shares changing hands at last check today with its beta currently measuring 0.50. Company’s recent per share price level of $155.02 trading at -$0.38 or -0.24% at last check today assigns it a market valuation of $373.23B. That most recent trading price of JNJ’s stock is at a discount of -8.92% from its 52-week high price of $168.85 and is indicating a premium of 7.67% from its 52-week low price of $143.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.43 million shares which gives us an average trading volume of 6.49 million if we extend that period to 3-months.
For Johnson & Johnson (JNJ), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.12. Splitting up the data highlights that, out of 19 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 8 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 2.04 in the current quarter.
Johnson & Johnson (NYSE:JNJ) trade information
Upright in the red during last session for losing -0.24%, in the last five days JNJ remained trading in the red while hitting it’s week-highest on Friday, 11/22/24 when the stock touched $155.02 price level, adding 1.34% to its value on the day. Johnson & Johnson’s shares saw a change of -1.10% in year-to-date performance and have moved -0.31% in past 5-day. Johnson & Johnson (NYSE:JNJ) showed a performance of -3.48% in past 30-days. Number of shares sold short was 17.48 million shares which calculate 2.54 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 177 to the stock, which implies a rise of 12.42% to its recent value today. Analysts have been projecting 150 as a low price target for the stock while placing it at a high target of 215. It follows that stock’s current price would jump 3.24% in reaching the projected high whereas dropping to the targeted low would mean a gain of 3.24% for stock’s current value.
Johnson & Johnson (JNJ) estimates and forecasts
Statistics highlight that Johnson & Johnson is scoring comparatively lower than the scores of other players of the relevant industry. The company added 5.69% of value to its shares in past 6 months, showing an annual growth rate of 0.10% while that of industry is 8.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 4.26% from the last financial year’s standing.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 22.45B for the same. And 6 analysts are in estimates of company making revenue of 22.04B in the next quarter. Company posted 21.39B and 21.38B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.27% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 0.33% while estimates for its earnings growth in next 5 years are of 6.00%.
JNJ Dividends
Johnson & Johnson is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 3.17%, the share has a forward dividend of 4.91 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 2.71%.
Johnson & Johnson (NYSE:JNJ)’s Major holders
Insiders are in possession of 0.09% of company’s total shares while institution are holding 73.10 percent of that, with stock having share float percentage of 73.17%. Investors also watch the number of corporate investors in a company very closely, which is 73.10% institutions for Johnson & Johnson that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at JNJ for having 229.04 million shares of worth $33.48 billion. And as of 2024-06-30, it was holding 9.5109 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 198.19 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2297 of outstanding shares, having a total worth of $28.97 billion.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 76.03 shares of worth $11.8 billion or 3.16% of the total outstanding shares. The later fund manager was in possession of 63.05 shares on Sep 30, 2024 , making its stake of worth around $9.79 billion in the company or a holder of 2.62% of company’s stock.
